Stockscreener 앱 받기
250.59
0.16%
-0.41
시간 외 거래:
250.59
전일 마감가:
$251.00
열려 있는:
$253.7
하루 거래량:
645.36K
Relative Volume:
0.97
시가총액:
$32.44B
수익:
$2.25B
순이익/손실:
$-278.16M
주가수익비율:
-115.48
EPS:
-2.17
순현금흐름:
$-42.59M
1주 성능:
-2.29%
1개월 성능:
-5.43%
6개월 성능:
-10.24%
1년 성능:
+61.94%
1일 변동 폭
$246.85
$253.70
1주일 범위
$246.61
$260.00
52주 변동 폭
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
BridgeBio’s Attruby Off To A Strong Start – But Alnylam Awaits - News & Insights
Ieq Capital LLC Acquires 34,613 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Vontobel Holding Ltd. Has $424,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update - MarketBeat
Rhumbline Advisers Sells 1,850 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Baillie Gifford & Co. Sells 846,741 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
BridgeBio: Strong Start For Attruby (NASDAQ:BBIO) - Seeking Alpha
Biotech Stocks Facing FDA Decision In March 2025 - RTTNews
Strategic Financial Concepts LLC Purchases Shares of 176,485 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Sells $169,204.23 in Stock - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg Sells 1,561 Shares - MarketBeat
Jeffrey V. Poulton Sells 967 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald Sells 1,440 Shares - MarketBeat
Canaccord Genuity Group Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Asset Management One Co. Ltd. - MarketBeat
Hemophilia Market Insights: Key Trends and Developments Across Different Types of Hemophilia | DelveInsight - GlobeNewswire Inc.
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Scotiabank Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Earnings Results - MarketBeat
Alnylam Delivers a Big Q4 Earnings Beat - MSN
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2024 Earnings Call Transcript - Insider Monkey
Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Alnylam Pharma: Hold Rating Due to Stable Financials and Uncertain Pipeline Prospects - TipRanks
Alnylam Pharmaceuticals CMO sells shares worth $14.99 million - MSN
Antisense Oligonucleotides Market to Witness Significant - openPR
ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals - MSN
Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Alnylam Pharmaceuticals’ Earnings Call Highlights Strong Growth - TipRanks
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
Van ECK Associates Corp Purchases 10,419 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Savant Capital LLC Boosts Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates - MSN
Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion - MSN
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y - MSN
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at Needham & Company LLC - MarketBeat
Learn to Evaluate (ALNY) using the Charts - Stock Traders Daily
Royal Bank of Canada Reiterates "Outperform" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Alnylam Earnings: Strong Patient Uptake Drives Growth; Anticipating Approval of Amvuttra for ATTR-CM - Morningstar
Embrace the competition from China, says Maraganore - BioCentury
RBC Raises Price Target on Alnylam Pharmaceuticals to $310 From $300, Keeps Outperform Rating - Marketscreener.com
Alnylam Pharmaceuticals Inc (ALNY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Alnylam Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Alnylam Pharmaceuticals Inc (ALNY) Q4 2024 Earnings Call Highlig - GuruFocus.com
Sumitomo Mitsui Trust Group Inc. Has $67.46 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals Inc (ALNY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Mirae Asset Global Investments Co. Ltd. Lowers Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam: Q4 Earnings Snapshot - mySA
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Alnylam: Waiting For Regulatory Updates In March (NASDAQ:ALNY) - Seeking Alpha
Reflections From Biotech Leader John Maraganore - News & Insights
Alnylam Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.81%
0.46%
자본화:
|
볼륨(24시간):